首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
【24h】

Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.

机译:拓扑异构酶I和IIα基因在食管癌,胃癌和结肠癌的肿瘤和正常组织中的表达及其关系。

获取原文
获取原文并翻译 | 示例
           

摘要

DNA topoisomerases are known to be nuclear enzymes that are important targets of topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in cancer chemotherapy. We investigated the mRNA expression of topo I and topo II alpha genes as assessed by northern blot analysis in tumor and the adjacent normal tissues of esophageal, gastric and colon cancers. The surgical specimens consisted of 18 tumor tissues and the adjacent normal tissues including 6 esophageal cancers, 6 gastric cancers and 6 colon cancers. We found that the mRNA expression of topo I gene was not significantly different between tumor and normal tissues in 18 surgical specimens, whereas the mRNA expression of topo II alpha gene in the all types of tumors was significantly higher than that of the adjacent normal tissues. Furthermore, the mRNA expression of topo II alpha gene in tumor and adjacent normal tissues was correlated with the S-phase population in cell cycle. Of great importance was the significant relationship between mRNA expression of topo I and topo II alpha genes in tumor and normal tissues was found in esophageal and colon cancers (p < 0.05), except in gastric cancers. These results indicate that the rationale in tumor specific chemotherapy with topo II inhibitors was based on the finding of its higher expression of topo II alpha gene in tumors than that of normal tissues, an important target of topo II inhibitors, and suggest that the sequential chemotherapy targeting topo I and topo II enzymes by modulating topo II alpha expression by topo I inhibitors might be more effective in esophageal and colon cancers, in terms of their relationship between topo I and topo II alpha expression in tumor cells.
机译:已知DNA拓扑异构酶是核酶,是癌症化学疗法中拓扑异构酶I(拓扑I)和拓扑异构酶II(拓扑II)抑制剂的重要靶标。我们调查了北部和北部地区的食管癌,胃癌和结肠癌的正常组织中通过Northern blot分析评估的topo I和topo II alpha基因的mRNA表达。手术标本由18个肿瘤组织和邻近的正常组织组成,包括6例食道癌,6例胃癌和6例结肠癌。我们发现在18个手术标本中,肿瘤和正常组织之间topo I基因的mRNA表达没有显着差异,而在所有类型的肿瘤中topo IIα基因的mRNA表达均显着高于邻近正常组织。此外,在肿瘤和邻近正常组织中,topo II alpha基因的mRNA表达与细胞周期的S期种群有关。极为重要的是,在食道癌和结肠癌中,肿瘤和正常组织中的topo I和topo II alpha基因的mRNA表达之间存在显着关系(p <0.05),而在胃癌中除外。这些结果表明,使用topo II抑制剂进行肿瘤特异性化疗的基本原理是基于发现topo II alpha基因在肿瘤中的表达高于正常组织的水平,而正常组织是topo II抑制剂的重要靶标,提示进行顺序化疗就肿瘤细胞中topo I和topo II alpha表达之间的关系而言,通过topo I抑制剂调节topo II alpha表达来靶向topo I和topo II酶可能在食道癌和结肠癌中更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号